KeyBanc analyst Brett Fishbin raised the firm’s price target on ResMed (RMD) to $274 from $269 on higher estimates, while keeping an Overweight rating on the shares. The firm believes investors will view ResMed’s Q3 release and call favorably, given solid results and definitively positive commentary on potential tariff exposure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- Resmed’s Strong Q3 Performance and Strategic Positioning Justify Buy Rating
- Resmed Inc. Reports Strong Q3 2025 Earnings
- Closing Bell Movers: Robert Half down 15% after earnings miss
- ResMed reports Q3 non-GAAP EPS $2.37, consensus $2.36
- ResMed appoints Salli Schwartz as Chief Investor Relations Officer